CA2669047A1 - Novel compounds and methods for their production - Google Patents

Novel compounds and methods for their production Download PDF

Info

Publication number
CA2669047A1
CA2669047A1 CA002669047A CA2669047A CA2669047A1 CA 2669047 A1 CA2669047 A1 CA 2669047A1 CA 002669047 A CA002669047 A CA 002669047A CA 2669047 A CA2669047 A CA 2669047A CA 2669047 A1 CA2669047 A1 CA 2669047A1
Authority
CA
Canada
Prior art keywords
strain
represent
ansamycin
compound according
analogue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002669047A
Other languages
English (en)
French (fr)
Inventor
Christine Martin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0622342.4A external-priority patent/GB0622342D0/en
Priority claimed from GB0720875A external-priority patent/GB0720875D0/en
Application filed by Individual filed Critical Individual
Publication of CA2669047A1 publication Critical patent/CA2669047A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002669047A 2006-11-09 2007-11-09 Novel compounds and methods for their production Abandoned CA2669047A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB0622342.4A GB0622342D0 (en) 2006-11-09 2006-11-09 Novel compounds and methods for their production
GB0622342.4 2006-11-09
GB0720875A GB0720875D0 (en) 2007-10-24 2007-10-24 Novel compounds and methods for their production
GB0720875.4 2007-10-24
PCT/GB2007/050679 WO2008056188A2 (en) 2006-11-09 2007-11-09 Novel compounds and methods for their production

Publications (1)

Publication Number Publication Date
CA2669047A1 true CA2669047A1 (en) 2008-05-15

Family

ID=39362724

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002669047A Abandoned CA2669047A1 (en) 2006-11-09 2007-11-09 Novel compounds and methods for their production

Country Status (10)

Country Link
US (1) US8492370B2 (https=)
EP (1) EP1973883B1 (https=)
JP (1) JP2010509306A (https=)
KR (1) KR20090075856A (https=)
AU (1) AU2007319014B2 (https=)
BR (1) BRPI0718564A2 (https=)
CA (1) CA2669047A1 (https=)
ES (1) ES2389740T3 (https=)
MX (1) MX2009004775A (https=)
WO (1) WO2008056188A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101688227B (zh) * 2007-01-26 2013-07-24 科森生物科学公司 通过工程化生物合成制备的大环内酰胺
KR101097850B1 (ko) 2009-02-24 2011-12-23 한국생명공학연구원 젤다나마이신 생합성 조절유전자 변이주 및 이를 이용한 젤다나마이신 생산방법
CN117695374B (zh) * 2024-01-25 2024-09-06 超越健康科技(浙江)有限公司 一种用于治疗帕金森病的生物药物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI943207A0 (fi) * 1992-01-06 1994-07-05 Pfizer 4,5-dihydrogeldanamysiinin ja sen hydrokinonin valmistusmenetelmä ja käyttö
EP1472230B1 (en) * 2002-02-08 2009-06-17 Conforma Therapeutic Corporation Ansamycins having improved pharmacological and biological properties
BRPI0418147A (pt) * 2003-12-23 2007-04-17 Infinity Pharmaceuticals Inc análogos de ansamicinas contendo benzoquinona e seus métodos de uso
JPWO2005061461A1 (ja) * 2003-12-24 2007-07-12 協和醗酵工業株式会社 ヒートショックプロテイン９０（ｈｓｐ９０）ファミリー蛋白質阻害剤
EP1863769A4 (en) 2005-03-11 2009-03-18 Univ Colorado HSP90 INHIBITORS, METHOD FOR THE PRODUCTION THEREOF AND THEIR APPLICATIONS
WO2007001049A1 (ja) * 2005-06-29 2007-01-04 Kyowa Hakko Kogyo Co., Ltd. ベンゼノイドアンサマイシン誘導体
BRPI0620624A2 (pt) * 2005-12-24 2011-11-16 Biotica Tech Ltd análogo de 21-deóximacbecina ou um sal farmaceuticamente aceitável do mesmo, método para a produção do mesmo, composição farmacêutica, cepas hospedeira e engenheirada, e, uso das mesmas
CN101012196A (zh) * 2006-12-27 2007-08-08 中国人民解放军军事医学科学院毒物药物研究所 芳香化格尔德霉素类衍生物及其制备方法和用途
CN101688227B (zh) * 2007-01-26 2013-07-24 科森生物科学公司 通过工程化生物合成制备的大环内酰胺

Also Published As

Publication number Publication date
EP1973883B1 (en) 2012-07-11
JP2010509306A (ja) 2010-03-25
WO2008056188A2 (en) 2008-05-15
ES2389740T3 (es) 2012-10-31
KR20090075856A (ko) 2009-07-09
US20110021481A1 (en) 2011-01-27
US8492370B2 (en) 2013-07-23
EP1973883A2 (en) 2008-10-01
AU2007319014A1 (en) 2008-05-15
BRPI0718564A2 (pt) 2014-03-11
MX2009004775A (es) 2009-05-21
WO2008056188A3 (en) 2008-07-31
AU2007319014B2 (en) 2013-03-28

Similar Documents

Publication Publication Date Title
US20090209494A1 (en) 21-deoxymacbecin analogues useful as antitumor agents
US20090253667A1 (en) 18 ,21-Didesoxymacbecin Derivatives for the Treatment of Cancer
US20100068203A1 (en) 17-Oxymacbecin Derivatives and Their Use in the Treatment of Cancer and/or B-Cell Malignancies
AU2007319014B2 (en) Novel compounds and methods for their production
US20110160175A1 (en) 18,21-Didesoxymacbecin Derivatives for the Treatment of Cancer
US20090117127A1 (en) Novel Compounds and Methods for Their Production
US20090209507A1 (en) 15-O-Desmethylmacbecin Derivatives and Their Use in the Treatment of Cancer or B-Cell Malignancies
US20110091452A1 (en) 4,5-Dihydromacbecin Derivatives and Their Use in the Treatment of Cancer or B-Cell Malignancies
US20090298804A1 (en) Novel Compounds and Methods for Their Production
CA2679224A1 (en) Novel compounds
EP2079700A1 (en) 18, 21-didesoxymacbecin derivatives for the treatment of cancer

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20150120